10/29/2012 – Lilly trials boost amyloid link to Alzheimer's-analysis

Levels of a protein believed to be a main cause of Alzheimer’s disease rose in the blood of patients treated with Eli Lilly’s experimental drug in late-stage trials, suggesting the protein, beta amyloid, was removed from the brain as intended, researchers said on Monday.

Read the full article at Reuters.